Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh Buyukkaramikli; Saskia de Groot; R Riemsma; D Fayter; N Armstrong; P Portegijs; S Duffy; J Kleijnen; Maiwenn Al

doi:10.1007/s40273-018-0708-4

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh Buyukkaramikli, Saskia de Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen, Maiwenn Al

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

7 Downloads (Pure)

Original language	English
Journal	Pharmacoeconomics (Print)
DOIs	https://doi.org/10.1007/s40273-018-0708-4
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40273-018-0708-4

Repub_111392_O-A.pdfFinal published version, 1.04 MB

http://hdl.handle.net/1765/111392

Cite this

Buyukkaramikli, N., de Groot, S., Riemsma, R., Fayter, D., Armstrong, N., Portegijs, P., Duffy, S., Kleijnen, J., & Al, M. (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print). https://doi.org/10.1007/s40273-018-0708-4

@article{90fa683dc17b44b68161d5b4da23f216,

title = "Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

author = "Nasuh Buyukkaramikli and {de Groot}, Saskia and R Riemsma and D Fayter and N Armstrong and P Portegijs and S Duffy and J Kleijnen and Maiwenn Al",

year = "2018",

doi = "10.1007/s40273-018-0708-4",

language = "English",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis",

}

Buyukkaramikli, N, de Groot, S, Riemsma, R, Fayter, D, Armstrong, N, Portegijs, P, Duffy, S, Kleijnen, J & Al, M 2018, 'Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics (Print). https://doi.org/10.1007/s40273-018-0708-4

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Buyukkaramikli, Nasuh; de Groot, Saskia; Riemsma, R et al.
In: Pharmacoeconomics (Print), 2018.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Buyukkaramikli, Nasuh

AU - de Groot, Saskia

AU - Riemsma, R

AU - Fayter, D

AU - Armstrong, N

AU - Portegijs, P

AU - Duffy, S

AU - Kleijnen, J

AU - Al, Maiwenn

PY - 2018

Y1 - 2018

U2 - 10.1007/s40273-018-0708-4

DO - 10.1007/s40273-018-0708-4

M3 - Article

SN - 1170-7690

JO - PharmacoEconomics

JF - PharmacoEconomics

ER -